Lenaerts A, Codden Th, Van Cauter J, Meunier J C, Henry J P, Ligny G
Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.
Acta Gastroenterol Belg. 2002 Jan-Mar;65(1):1-5.
The aim of this study was to examine the effects of spironolactone, clonidine and the association of clonidine-spironolactone on renin-aldosterone and sympathetic systems, renal function, systemic hemodynamics and mobilization of ascites in 32 alcoholic cirrhotic patients with marked increase in sympathetic system.
Measurements were taken before and after an 8-day treatment with spironolactone (200 mg/day), after an 8-day treatment with clonidine (0.150 mg/day) and 10 days after adjunction of spironolactone (200 mg/day) to clonidine.
Three patients abandoned the treatment or were excluded because lack of compliance. Spironolactone alone induced an increase in renin-aldosterone and sympathetic systems without any remarkable increase of natriuresis and body weight loss. Given for 8 days, clonidine alone induced a significant decrease in plasma norepinephrine associated with a significant increase in glomerular filtration rate without effect on natriuresis. In contrast, 10 days after adjunction of spironolactone to clonidine, plasma renin and aldosterone significantly decreased, natriuresis increased (from 7.4 +/- 0.7 to 41.6 +/- 3.2 mEq/24 h) and body weight decreased (from 66.03 +/- 2.3 to 63.5 +/- 2.3 kg) without adverse effects.
In cirrhotic patients with ascites and marked activation of sympathetic nervous system, spironolactone (200 mg/day) is unable to mobilize ascites. In these patients, after 8 days, clonidine decreases sympathetic activity, increases glomerular filtration rate and after 18 days, decreases plasma renin and aldosterone concentrations allowing a better action of spironolactone. The association clonidine-spironolactone enhances natriuresis and body weight loss.
本研究旨在探讨螺内酯、可乐定以及可乐定 - 螺内酯联合用药对32例交感神经系统显著亢进的酒精性肝硬化患者肾素 - 醛固酮系统、交感神经系统、肾功能、全身血流动力学及腹水消退的影响。
在给予螺内酯(200毫克/天)治疗8天前后、给予可乐定(0.150毫克/天)治疗8天前后以及在可乐定(0.150毫克/天)基础上加用螺内酯(200毫克/天)治疗10天后进行各项测量。
3例患者因依从性差而中断治疗或被排除。单独使用螺内酯可使肾素 - 醛固酮系统和交感神经系统活性增加,但尿钠排泄和体重减轻无明显增加。单独给予可乐定8天可使血浆去甲肾上腺素显著降低,同时肾小球滤过率显著增加,但对尿钠排泄无影响。相比之下,在可乐定基础上加用螺内酯10天后,血浆肾素和醛固酮显著降低,尿钠排泄增加(从7.4±0.7增至41.6±3.2毫当量/24小时),体重减轻(从66.03±2.3降至63.5±2.3千克),且无不良反应。
在伴有腹水且交感神经系统明显激活的肝硬化患者中,螺内酯(200毫克/天)无法促进腹水消退。在这些患者中,可乐定在用药8天后可降低交感神经活性,增加肾小球滤过率,用药18天后可降低血浆肾素和醛固酮浓度,从而使螺内酯发挥更好的作用。可乐定与螺内酯联合使用可增强尿钠排泄和体重减轻。